	US 12,005,101 B2
	Modulation of proprotein convertase subtilisin/kexin 9 expression (PCSK9) with HSP 27 and/or HSP25
Edward R. M. O'Brien, Calgary (CA); Chunhua Shi, Pearland, TX (US); and Yong-Xiang Chen, Calgary (CA)
Assigned to PEMI31 Therapeutics Inc., Calgary (CA)
Filed by PEMI31 Therapeutics Inc., Calgary (CA)
Filed on Oct. 29, 2021, as Appl. No. 17/515,001.
Application 17/515,001 is a continuation of application No. 15/756,282, granted, now 11,439,696, previously published as PCT/CA2016/051018, filed on Aug. 29, 2016.
Claims priority of provisional application 62/211,190, filed on Aug. 25, 2015.
Prior Publication US 2022/0118068 A1, Apr. 21, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); A61K 38/17 (2006.01); A61K 39/39 (2006.01); A61K 39/395 (2006.01); A61P 3/06 (2006.01); C07K 14/47 (2006.01); C07K 16/18 (2006.01); C12N 9/58 (2006.01); G01N 33/543 (2006.01)

CPC A61K 39/0005 (2013.01) [A61K 38/1709 (2013.01); A61K 39/39 (2013.01); A61K 39/3955 (2013.01); A61P 3/06 (2018.01); C07K 14/47 (2013.01); C07K 14/4703 (2013.01); C07K 16/18 (2013.01); C12N 9/58 (2013.01); G01N 33/54326 (2013.01); A61K 39/395 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/55566 (2013.01); G01N 2333/4703 (2013.01)]

16 Claims

1. A method for increasing serum levels of HSP27 and/or serum levels of HSP27 antibodies in a human subject comprising administration, to the human subject, of an effective dose of a pharmaceutical composition comprising:

a HSP27 protein that shares at least 85% sequence identity with the amino acid sequence set forth in SEQ.ID NO: 4 wherein the concentration of said HSP27 protein, is in the range of 25 μg/mL to 250 μg/mL; and

an adjuvant wherein the concentration of said adjuvant is in the range of 25 μg/mL to 250 μg/mL;

together with a pharmaceutically acceptable diluent or carrier.